The Trump administration has awarded Sanofi (NYSE:SNY) and GlaxoSmithKline (NYSE:GSK) a contract for up to $1.2 billion to develop, manufacture and deliver a vaccine for COVID-19, the companies announced today.
The vaccine candidate is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK’s established pandemic adjuvant (immunity-boosting) technology. Manufacturing will take place in the U.S.
Get the full story on our sister site, Pharmaceutical Processing World.